Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer
1834.4000 -31.10 (-1.67%)
NSE Nov 17, 2026 15:31 PM
Volume: 230.0K
 

logo
Ipca Laboratories Ltd.
17 Feb 2026, 12:00AM
1834.40
-1.67%
Prabhudas Lilladhar
Ipca reported strong EBITDA of Rs5.3bn (up 19% YoY) which was 10% above our estimates. Company has witnessed 400bps GMs expansion ex Unichme for 9MFY26 which should sustain given product mix and softer raw material prices. Export API business witnessed recovery in 9MFY26 with 26% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady...
Ipca Laboratories Ltd. is trading above its 200 day SMA of 1700.7
More from Ipca Laboratories Ltd.
Recommended